91麻豆精品国产综合久久久,人人玩人人添人人澡超碰,五月婷婷六月激情综合,国产一级二级三级久久

訂購(gòu)信息
上海拜力生物科技公司
Tel:400-968-7988    021-33779008
HCI-2509(SP2509),ReversibleLSD1Inhibitor.
品牌:Xcessbio
貨號(hào):M60160-2s
規(guī)格:2 mg solid
貨期:
應(yīng)用: 點(diǎn)擊這里給我發(fā)消息  咨詢客服

HCI-2509(SP2509),ReversibleLSD1Inhibitor.

商品詳情 參考文獻(xiàn) 相關(guān)資料
Product Information
Molecular Weight: 437.90
Formula: C19H20ClN3O5S
Purity: ≥98%
CAS#: 1423715-09-6
Solubility: DMSO up to 50 mM
Chemical Name: (E)-N'-(1-(5-chloro-2-hydroxyphenyl)ethylidene)-3-(morpholinosulfonyl)benzohydrazide
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:


HCI-2509 (also named as SP2509 or LSD1-C12) is a highly potent, specific, and reversible Lysine Specific Demethylase-1 (LSD1) inhibitor. It inhibits LSD1 in biochemical assay with an IC50 ~13 nM, and has no activity against monoamine oxidase proteins MAO-A and MAO-B (>300 μM). HCI-2509 is a non-competitive inhibitor to bind LSD1, changes its solution dynamics in a manner distinct from TCP. It has minimal inhibition of CYPs and hERG, shows cellular activity against several cancer cell lines including endometrial, breast, colorectal, pancreatic, and prostate cancer (IC50 ~0.3-2.5 μM). HCI-2509 displayed sing-agent efficacy in multiple xenograft models and had good PK/PD relationship by using tumor histone H3K4 and H3K9 methylation. HCI-2509 serves as a very useful chemical probe to study the target biology of LSD1.

How to Use:


In vitro: HCI-2509 was used at 1 μM in vitro.
In vivo: HCI-2509 was administered through IP injection at 25-30 mg/kg once per day in xenografts models.

Reference:

  • 1. Fiskus W, et al. Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. (2014) Leukemia. 28(11):2155-64.?
  • 2. Sorna V, et al. High-Throughput Virtual Screening Identifies Novel N'-(1-Phenylethylidene)-benzohydrazides as Potent, Specific, and Reversible LSD1 Inhibitors. (2013) J Med Chem. 56(23):9496-508.?
  • 3. Wiles ET, et al. BCL11B is up-regulated by EWS/FLI and contributes to the transformed phenotype in Ewing sarcoma. (2013) PLoS One. 8(3):e59369.?
  • 4. Bret J. Stephens, et al.: Activity of the LSD1 inhibitor HCI-2509 in ER-negative breast cancer cells. (2012) AACR Chicago. Abstract 1045. Cancer Research: April 15, 2012; Volume 72, Issue 8, Supplement 1.
  • 5. Emily R, et al. Inhibition of LSD1 disrupts global EWS/ETS transcriptional function in Ewing sarcoma. (2014) AACR San Diego. Abstract 3679.?

? ? ??
? ? ??


Products are for research use only. Not for human use.

熱銷產(chǎn)品
熱銷產(chǎn)品排行榜
  • 關(guān)于我們
  • 購(gòu)物流程
  • 支付方式
  • 配送方式

請(qǐng)打開QQ掃碼聯(lián)系
Copyright@ 2003-2024  進(jìn)口試劑采購(gòu)網(wǎng)版權(quán)所有     

BIOLEAF熱搜   BIOLEAF試劑盒   BIOLEAF ELISA   BIOLEAF試劑   BIOLEAF品牌   BIOLEAF抗體   BIOLEAF耗材   BIOLEAF小儀器

sitemap   細(xì)胞庫(kù)查詢   危險(xiǎn)品圖標(biāo)

本公司網(wǎng)站所展示銷售的產(chǎn)品僅供科研!

         滬ICP備08023583號(hào)-6     
產(chǎn)品咨詢
QQ掃碼溝通
在線客服
服務(wù)電話
400-968-7988
掃碼關(guān)注
微信公眾號(hào)二維碼

滬公網(wǎng)安備 31011202007338號(hào)

乳源| 郯城县| 德江县| 普兰县| 浪卡子县| 五华县| 宿州市| 安陆市| 遵化市| 泽州县| 衡水市| 会泽县| 茌平县| 隆安县| 大化| 麻栗坡县| 姚安县| 若羌县| 贵南县| 北辰区| 乐山市| 江陵县| 满洲里市| 湘西| 宜宾市| 台中市| 达孜县| 南昌市| 临澧县| 龙州县| 池州市| 东至县| 斗六市| 北京市| 辉南县| 汉阴县| 安平县| 曲周县| 惠安县| 德安县| 海门市|